BAC in pact with BMS
Adnectins are designed by using BMS‘ proprietary PROfusion technology to either block or stimulate the action of specific targets across a range of therapeutic areas. Under the agreement,
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.